TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03387150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9%; administered by IM injection
Study: NCT00403403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
Study: NCT02708758

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy
Description: individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
Study: NCT05079555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic rehab
Description: Patients using the robotic platform SWalker
Study: NCT01292668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-5-aminolevulinate hydrochloride cream
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-5-aminolevulinate hydrochloride cream
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo light-emitting diode photodynamic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Undergo laser light photodynamic therapy
Study: NCT02086838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theragran Hematinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight iron dextran
Study: NCT01390051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innohep (Tinzaparin)
Description: Dose: 4,500 IU daily in half of the study populationrandomised to treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinzaparin
Description: Dose 4,500 IE daily
Study: NCT02156219

Intervention type: OTHER
Intervention: Separation of women and men in the metro of Mexico City
Description: The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop.
Study: NCT02724072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoraflex™ Hybrid Device
Description: Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
Study: NCT03985098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention arm
Description: The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
Study: NCT02110927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous microcurrent
Description: Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: 50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
Study: NCT02060253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT04271488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasurgratinib
Description: Tasurgratinib oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasurgratinib
Description: Tasurgratinib oral capsule.
Study: NCT00096005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06692049

Intervention type: PROCEDURE
Intervention: Gonadectomy
Description: Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation
Study: NCT03654248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get Organized group intervention
Description: Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
Study: NCT03951727

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular treatment for PAD
Description: Long femoropopliteal stenting with SuperA devices
Study: NCT03654248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individual Occupational Therapy
Description: Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
Study: NCT02060253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Given IV
Study: NCT02583672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
Study: NCT02152436

Intervention type: OTHER
Intervention: Simulation - based curriculum
Description: Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
Study: NCT04913870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin Receptor Blockers treatment for 2 years.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 2 years.
Study: NCT04267562

Intervention type: DEVICE
Group type: OTHER
Intervention: Minitouch System
Description: The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
Study: NCT02172651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
Study: NCT02344355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.
Study: NCT05347797

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
Study: NCT02998164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: augmentative and alternative communication technology

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No change to the therapy care received
Study: NCT01861301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT03820258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.
Study: NCT02891954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
Study: NCT03141164

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: computerized training
Description: Computerized training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized training
Description: Computerized training
Study: NCT03820258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.
Study: NCT01589835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Description: Green prescription with support from facilitator

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle changes
Description: Green prescription with support from facilitator
Study: NCT01685008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR00208 (formerly Xmab 5574)
Study: NCT01711801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Single dose, in fed and fasted state
Study: NCT04626479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 400 mg Q6W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 400 mg Q6W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: Administered via IV infusion at a dose of 800 mg/200 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Administered via oral tablet at a dose of 120 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Administered via oral tablet at a dose of 120 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD
Study: NCT03913637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
Study: NCT04305041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days
Study: NCT04626479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a dose of 400 mg/25 mg Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibostolimab/Pembrolizumab
Description: Administered via IV infusion at a dose of 200 mg/200 mg Q6W
Study: NCT04305041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsules at a specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Administered via oral capsules at a specified dose on specified days
Study: NCT03258593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
Study: NCT01783522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine
Description: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT03187951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Questionnaire and Nutritional Counseling
Description: Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
Study: NCT03258593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
Study: NCT00011193

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.